Jasper Merges with Kira for $292M | Pharma and Biotech Daily

Biotech Daily is now open for sponsors and job of the week listings. If you want to reach biotech or pharma operators, scientists, founders, and investors, you can book a single episode, a full week, or promote an open role, all directly by visiting sponsor.o with.ai. That's sponsor.o w i t h.ai. Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of industry shaping events, reflecting the ever-evolving landscape of drug development, regulatory challenges, and strategic maneuvers. In a significant move within the sector, Jasper Therapeutics has merged with Kira Pharmaceuticals, a strategic decision aimed at expanding its footprint in autoimmune therapeutics. This merger brings to Jasper a valuable acid in KP-104, a dual inhibitor with the potential to address rare diseases, an area of considerable unmet need. Such consolidations highlight an industry trend where companies seek to bolster their portfolios with promising candidates that can tackle complex medical conditions. The merger exemplifies how strategic expansions are becoming increasingly integral to maintaining competitive edges in the biotech arena. Turning to clinical trials, Takeda Zasacitinib has demonstrated promising results for patients suffering from moderate to plaque psoriasis In phase 3 trials a significant 75 of patients achieved clearance of scalp psoriasis Zasacitinib operates as a TYK2 inhibitor, targeting the IL-23 pathway, a crucial mechanism in autoimmune diseases like psoriasis. This breakthrough promises to enhance patient care by providing a more effective treatment option for those struggling with difficult-to-treat psoriasis. On the regulatory front, Novartis Fabalta, Iptacopan, has gained FDA approval for its role in slowing kidney function decline in patients with primary immunoglobulin and nephropathy. As a small molecule complement inhibitor, Iptacopan introduces a novel treatment class for this autoimmune kidney disorder. This approval underscores ongoing innovation within nephrology and offers renewed hope for improved patient outcomes. Recent regulatory updates also saw Novartis securing full FDA approval for Fabalta, an affirmation of progress in addressing immunoglobulin and nephropathy through innovative therapeutic options. Business development remains a driving force in shaping industry landscapes. The acquisition of Mission Therapeutics Aki candidate MTX 652 by Demerics is a prime example. This $5 million deal, with potential milestones up to million reflects high stakes and ambitions to advance treatments for acute kidney injuries a field with significant unmet medical needs The integration of artificial intelligence continues to revolutionize drug discovery processes Akemiya collaboration with Sanofi highlights this trend showcasing AI crucial role in expediting drug development and uncovering novel therapeutic targets. Their partnership potentially worth $140 million underscores AI's transformative potential within pharmaceutical research. Notably, Nobel laureate Jennifer Doudna's foray into AI-powered protein design signifies an exciting intersection between gene editing technology and artificial intelligence. Her involvement signals potential revolutions in drug discovery through enhanced precision in protein engineering. However, regulatory challenges persistently loom over the industry. Novo Nordisk and Alvotec have faced FDA scrutiny concerning manufacturing deficiencies, an issue that accentuates the importance of stringent quality control and operational excellence in biologics manufacturing. The American Society of Health System Pharmacists, ASHP, report on U.S. drug shortages during Q2-2026 reveals vulnerabilities within supply chains, notably impacting oncology drugs. These shortages emphasize the critical need for robust strategies to ensure consistent drug availability for essential therapies. Furthermore geopolitical dynamics are influencing pharmaceutical supply chains A U Senate bill aimed at increasing transparency highlights concerns over China dominance in drug ingredient supplies an issue necessitating strategic adjustments by globally operating companies. Elsewhere within the sector, GSK made headlines by discontinuing the development of its chronic cough treatment Kamlipixin following mixed phase 3 trial results, a setback illustrating the critical nature of trial outcomes in determining drug viability and market potential. In market trends, biotech IPOs have surged during the first half of 2026, a sign of robust investor interest fueled by innovations in favorable funding environments despite associated market volatility risks. Strategic adjustments continue across companies with mergers and acquisitions leading to workforce reductions, projected layoffs exceeding 14,000 within biopharma during H1 2026, as organizations streamline operations or pivot towards more promising research domains. Lastly, Merck's FDA approval for an oral PCSK9 inhibitor marks a significant achievement in cardiovascular care, representing another stride forward in therapeutic innovation. In summary, these developments encapsulate a landscape defined by scientific pursuits yielding mixed results amidst evolving regulatory interactions and strategic realignments, all contributing towards innovative healthcare solutions while navigating complex industry dynamics.